Background and Objectives: The biological behavior of gliomas is influenced by various factors including molecular features and treatment response. This study investigates the prognostic implications of a second tumor in patients with glioma at time of diagnosis. Given the increasing number of patients presenting with multiple primary malignancies due to improved cancer survival and diagnostic accuracy, understanding the influence of double tumor burden on glioma outcomes is of growing clinical relevance. Methods: We retrospectively analyzed adult patients with intracranial gliomas (WHO grade 2–4), who were surgically treated between 2015 and 2022 at our institution. Patients were categorized into two groups: glioma only and glioma plus additional solid malignancy. We compared progression-free survival (PFS) and overall survival (OS) using Kaplan–Meier and Cox regression analyses. Results: Among 426 glioma patients, 75 (17.6%) harbored a second non-brain tumor. Patients with multiple primaries showed significantly poorer OS (median 6 vs. 14 months,p= 0.002). No significant difference in PFS or OS was observed for patients in case the systemic tumor was in complete remission as compared to those with sole glioma. However, patients with progressive or stable systemic tumor had significantly worse outcomes regarding OS (p< 0.05). Conclusions: Our findings suggest that the presence of a second systemic malignancy is an independent prognostic factor for worse outcome. Further studies are mandated to elucidate genetic situations and refine therapeutic strategies for these patients.
背景与目的：胶质瘤的生物学行为受多种因素影响，包括分子特征和治疗反应。本研究探讨诊断时合并第二原发肿瘤对胶质瘤患者预后的影响。随着癌症生存率提高和诊断准确性上升，多原发恶性肿瘤患者日益增多，明确双重肿瘤负荷对胶质瘤预后的影响具有重要临床意义。方法：我们回顾性分析了2015年至2022年间在本机构接受手术治疗的成人颅内胶质瘤患者（WHO 2-4级）。将患者分为两组：单纯胶质瘤组和胶质瘤合并其他实体肿瘤组。采用Kaplan-Meier法和Cox回归分析比较两组患者的无进展生存期（PFS）和总生存期（OS）。结果：在426例胶质瘤患者中，75例（17.6%）伴有第二非脑部肿瘤。多原发肿瘤患者OS显著更差（中位生存期6个月 vs 14个月，p=0.002）。若全身性肿瘤处于完全缓解状态，其PFS或OS与单纯胶质瘤患者无显著差异；但全身性肿瘤处于进展期或稳定期的患者OS显著更差（p<0.05）。结论：本研究提示合并第二全身性恶性肿瘤是预后不良的独立危险因素。需进一步研究阐明此类患者的遗传学特征并优化治疗策略。
肿瘤(癌症)患者之家